(LAIB) Masterclass
Pharmacotherapy Area Based Networks
The proven safety record of buprenorphine, combined with a weekly to monthly dosing schedule provide very good reasons for both patients and prescribing clinicians to engage with this new treatment.
Compare and contrast the effectiveness of long-acting injectable buprenorphine (LAIB) to sublingual buprenorphine and oral methadone in a harm minimisation setting
Outline the indications for treatment, as well as patient - centred factors that would make them less suited for treatment with long-acting injectable buprenorphine.
Describe the legal and logistic considerations for LAIB therapy including examples of how these are practically addressed.
Demonstrate best practice administration of both Buvidal and Sublocade formulations of LAIB.
David's areas of interest include acute illicit stimulant intoxication, improved methadone, buprenorphine and other opiate prescribing and the development of improved health and NSP services for people who inject drugs
Frankston Healthcare.
Rob has served with the RACGP Addiction Medicine Committee and the National Faculty of Addiction Medicine; and has been active the in the FMP area on the Domestic Violence Advisory Group, the GP Network Mental Health Committee and the Pharmacotherapy Expert Advisory Group
Angelo Pricolo is a Melbourne based pharmacist who has been involved in the treatment of addiction and harm minimisation for 30 years. He has been a pharmacy owner, previous National Councillor of the Pharmacy Guild, and a sessional tutor at Monash University
Terrie helped to establish the Pharmacotherapy and Wellbeing Clinic Service at the Sale Hospital's consulting suites that offers client consultations (outpatient) providing Opioid Replacement Therapy.
Brought to you by Pharmacotherapy Area Based Networks